PMID- 35994620
OWN - NLM
STAT- MEDLINE
DCOM- 20221205
LR  - 20230420
IS  - 1529-7535 (Print)
IS  - 1529-7535 (Linking)
VI  - 23
IP  - 12
DP  - 2022 Dec 1
TI  - Proton Pump Inhibitor Use and Associated Infectious Complications in the PICU: 
      Propensity Score Matching Analysis.
PG  - e590-e594
LID - 10.1097/PCC.0000000000003063 [doi]
AB  - OBJECTIVES: We aimed to evaluate the association between proton pump inhibitor 
      (PPI) exposure and nosocomial infection (NI) during PICU stay. DESIGN: Propensity 
      score matched analysis of a single-center retrospective cohort from January 1, 
      2017, to December 31, 2018. SETTING: Tertiary medical and surgical PICU in 
      France. PATIENTS: Patients younger than 18 years old, admitted to the PICU with a 
      stay greater than 48 hours. INTERVENTION: Patients were retrospectively allocated 
      into two groups and compared depending on whether they received a PPI or not. 
      MEASUREMENTS AND MAIN RESULTS: Seven-hundred fifty-four patients were included of 
      which 231 received a PPI (31%). PPIs were mostly used for stress ulcer 
      prophylaxis (174/231; 75%), but upper gastrointestinal bleed risk factors were 
      rarely present (18%). In the unadjusted analyses, the rate of NI was 8% in the 
      PPI exposed group versus 2% in the nonexposed group. After propensity score 
      matching ( n = 184 per group), we failed to identify an association between PPI 
      exposure and greater odds of NI (adjusted odds ratio 2.9 [95% CI, 0.9-9.3]; p = 
      0.082). However, these data have not excluded the possibility that there is up to 
      nine-fold greater odds of NI. CONCLUSIONS: This study highlights the prevalent 
      use of PPIs in the PICU, and the potential association between PPIs and nine-fold 
      greater odds of NI is not excluded.
CI  - Copyright (c) 2022 by the Society of Critical Care Medicine and the World 
      Federation of Pediatric Intensive and Critical Care Societies.
FAU - Goyer, Isabelle
AU  - Goyer I
AD  - Department of Pharmacy, CHU de Caen, Caen, F-14000, France.
FAU - Lacotte, Edouard
AU  - Lacotte E
AD  - Department of Pediatrics, CHU de Rouen, Rouen, F-76000, France.
FAU - Montreuil, Julien
AU  - Montreuil J
AD  - Department of Pharmacy, CHU de Caen, Caen, F-14000, France.
FAU - Thibon, Pascal
AU  - Thibon P
AD  - CHU de Caen, Regional Center for Infection Prevention and Control, F-14000, 
      France.
FAU - Briant, Anais R
AU  - Briant AR
AD  - Department of Biostatistics, CHU de Caen, Caen, F-14000, France.
FAU - Dupont, Claire
AU  - Dupont C
AD  - Department of Pediatrics, CHU de Caen, Caen, F-14000, France.
AD  - Universite Caen Normandie, Medical School, Caen, F-14000, France.
FAU - Parienti, Jean-Jacques
AU  - Parienti JJ
AD  - Department of Biostatistics, CHU de Caen, Caen, F-14000, France.
AD  - Universite Caen Normandie, Medical School, Caen, F-14000, France.
AD  - Universite Caen Normandie, INSERM U1311 DYNAMICURE, Caen, F-14000, France.
FAU - Brossier, David
AU  - Brossier D
AD  - Department of Pediatrics, CHU de Caen, Caen, F-14000, France.
AD  - Universite Caen Normandie, Medical School, Caen, F-14000, France.
AD  - Pediatric Intensive Care Unit, CHU de Caen, Caen, F-14000, France.
AD  - Universite Caen Normandie, GREYC, Caen, F-14000, France.
AD  - Universite de Montreal, CHU Sainte Justine Research Center, Montreal, QC, Canada.
LA  - eng
PT  - Journal Article
DEP - 20220822
PL  - United States
TA  - Pediatr Crit Care Med
JT  - Pediatric critical care medicine : a journal of the Society of Critical Care 
      Medicine and the World Federation of Pediatric Intensive and Critical Care 
      Societies
JID - 100954653
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Histamine H2 Antagonists)
SB  - IM
MH  - Humans
MH  - Adolescent
MH  - Child
MH  - *Proton Pump Inhibitors/adverse effects
MH  - *Histamine H2 Antagonists/therapeutic use
MH  - Retrospective Studies
MH  - Propensity Score
MH  - Intensive Care Units, Pediatric
COIS- Dr. Goyer received funding from Braun Medical. Dr. Dupont received funding from 
      Abbvie. The remaining authors have disclosed that they do not have any potential 
      conflicts of interest.
EDAT- 2022/08/23 06:00
MHDA- 2022/12/06 06:00
CRDT- 2022/08/22 15:12
PHST- 2022/08/23 06:00 [pubmed]
PHST- 2022/12/06 06:00 [medline]
PHST- 2022/08/22 15:12 [entrez]
AID - 00130478-202212000-00023 [pii]
AID - 10.1097/PCC.0000000000003063 [doi]
PST - ppublish
SO  - Pediatr Crit Care Med. 2022 Dec 1;23(12):e590-e594. doi: 
      10.1097/PCC.0000000000003063. Epub 2022 Aug 22.